GKOS - Glaukos Corp logo

Glaukos Corp

GKOS

Glaukos Corporation develops therapies and devices for glaucoma, corneal disorders, and retinal diseases, including micro-bypass stents and drug delivery systems. It sells products primarily to ambulatory surgery centers, hospitals, and physician practices.

⚕️ Healthcare NYSE Listed 2015 $ USD
$1,000 invested 10 years ago →$5,128today

Score Overview

1 Year
Score
Net Growth-0.19%
Net TrendShrank
Net Income Consistency—
Rev Growth20.77%
Rev TrendGrew
Revenue Consistency—
5 Years
Score2.6
Net Growth-279.18%
Net TrendNever
Net Income Consistency—
Rev Growth108.44%
Rev Trend80%
Revenue Consistency—
10 Years
Score
Net Growth-41x
Net Trend25%
Net Income Consistency
Rev Growth435.71%
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth-404.95%
Net Trend33%
Net Income Consistency
Rev Growth8x
Rev Trend82%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Glaukos Corp has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. GKOS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 178.88—
1 Year2025-10-23
$ 75.26137.68%
5 Years2021-10-22
$ 44.91298.31%
10 Years2016-10-21
$ 34.88412.84%
All Time2015-06-25
$ 31.22472.97%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 612M-$ 188M$ 286M
2025$ 507M-$ 187M$ 278M
2024$ 383M-$ 146M$ 318M
2023$ 314M-$ 134M$ 295M
2022$ 282M-$ 99M$ 352M
2021$ 294M-$ 49M$ 414M
2020$ 224M-$ 120M$ 404M
2019$ 236M$ 15M$ 173M
2018$ 181M-$ 12M$ 140M
2017$ 159M$ 119M
2016$ 114M$ 4M$ 95M
IPO2015$ 71M-$ 37M$ 91M
GKOS - Glaukos Corp logo

Glaukos Corp fundamental performance

Between 2020 and 2025, revenue grew from $ 224M to $ 507M and net income went from -$ 120M to -$ 187M. Revenue increased in 4 of those 5 years; net income in 0.

Across Glaukos Corp's full reported history, from 2015 to 2025, revenue grew from $ 71M to $ 507M and net income went from -$ 37M to -$ 187M. Revenue increased in 82% of the years measured; net income in 33%.

Glaukos Corp currently holds a 5-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.

Membership

Explore GKOS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies